Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer of Prostate Clear all
Recruiting Phase 2 Interventional

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

NCT07285057
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy

NCT00480857
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel (Taxotere)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

NCT00946881
View directory record Official record
Conditions
Prostate Cancer
Interventions
WST 11 -mediated -VTP
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05005728
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Combination Product · Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

NCT03103321
View directory record Official record
Conditions
Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage I Prostate Cancer, PSA Level Five to Ten, PSA Level Less Than Five, PSA Level Ten to Fifty
Interventions
Internet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration, Laboratory Biomarker Analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
28
States / cities
Bellflower, California • Los Angeles, California • Oakland, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 14, 2026, 10:47 AM EDT
Completed No phase listed Observational

Genetic Investigation of Solid Tumors Cohort

NCT01005225
View directory record Official record
Conditions
Prostate Cancer, Colon Cancer
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Sep 14, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

NCT01528774
View directory record Official record
Conditions
Melanoma
Interventions
Blood Draw
Other
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MVA 5T4, Docetaxel
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

NCT00305747
View directory record Official record
Conditions
Prostate Cancer
Interventions
BR-DIM
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Transpelvic Magnetic Stimulation to Improve Urogenital Function

NCT04488068
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
Sham Magnetic stimulation
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 80 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated No phase listed Observational

Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583

NCT00898833
View directory record Official record
Conditions
Prostate Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional

Safety Study of MGD009 in B7-H3-expressing Tumors

NCT02628535
View directory record Official record
Conditions
Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
Interventions
MGD009
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT02207504
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
Crizotinib, Enzalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

NCT00715078
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 14, 2026, 10:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

NCT04969315
View directory record Official record
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer (CRC), Endometrial Cancer, Ovarian Cancer
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

NCT00117949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
12
States / cities
Anaheim, California • Laguna Woods, California • San Bernardino, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Treatment Decision Intervention for Veterans With Prostate Cancer

NCT00012935
View directory record Official record
Conditions
Prostate Cancer
Interventions
Help with decision making on prostate cancer treatment
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 14, 2026, 10:47 AM EDT
Active, not recruiting Not applicable Interventional

Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy

NCT06599476
View directory record Official record
Conditions
Prostate Cancer
Interventions
BioProtect Balloon Implant™ System
Device
Lead sponsor
Advanced Radiation Centers of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217
View directory record Official record
Conditions
Over-Active Bladder
Interventions
Solifenacin succinate, Placebo
Drug
Lead sponsor
Advanced Research Network
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 14, 2026, 10:47 AM EDT
Completed No phase listed Observational

Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area

NCT00702104
View directory record Official record
Conditions
Prostate Cancer
Interventions
survey administration
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03137758
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
PCUR - 101
Drug
Lead sponsor
Pellficure Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

NCT00479635
View directory record Official record
Conditions
Prostate Cancer
Interventions
TPI 287
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palm Springs, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

NCT04060394
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Phase I and Phase II: LAE001/prednisone + afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 14, 2026, 10:47 AM EDT